{
    "clinical_study": {
        "@rank": "105703", 
        "arm_group": {
            "arm_group_label": "Brivaracetam", 
            "arm_group_type": "Experimental", 
            "description": "The subjects will be treated with Brivaracetam (BRV) tablets 200 mg/day during 12 weeks: four 25 mg tablets, twice daily.\nBased on the Investigator's judgement, at any time, the dose can be decreased to BRV 150 mg/day, 100 mg/day, or 50 mg/day. Flexible dosing, can be up- and down-titrated as needed.\nAt the end of the Treatment Period, the subject will either enter the N01372 long-term follow-up study or down-titrate during 4 weeks."
        }, 
        "brief_summary": {
            "textblock": "Trial N01395 is to evaluate the reduction of nonpsychotic behavioral side effects in\n      subjects with Epilepsy who switched to BRV 200 mg/day after discontinuing LEV due to such\n      side effects; as well as the efficacy, safety and tolerability of BRV. No statistical\n      hypothesis testing will be performed."
        }, 
        "brief_title": "Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Epilepsy", 
        "condition_browse": {
            "mesh_term": "Epilepsy"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject with well-characterized Epilepsy according to the 1989 International League\n             Against Epilepsy (ILAE) classification\n\n          -  Subject with Epilepsy who the investigator expects will benefit from Levetiracetam\n             (LEV) but for whom the investigator has decided to discontinue due to nonpsychotic\n             behavioral side effects following the introduction of LEV\n\n          -  Subject is currently receiving LEV at the recommended therapeutic dose (dose ranging\n             from 1 g/day to 3 g/day)\n\n          -  Subject currently treated with minimum 2 and maximum 3 Anti-Epileptic Drugs (AEDs)\n             including LEV. Vagal Nerve Stimulation (VNS) is allowed and will be counted as a\n             concomitant AED\n\n          -  Female subjects without childbearing potential (postmenopausal for at least 2 years,\n             bilateral oophorectomy or tubal ligation, complete hysterectomy) are eligible. Female\n             subjects with childbearing potential are eligible if they use a medically accepted\n             contraceptive method\n\n        Exclusion Criteria:\n\n          -  Subject has a lifetime history of suicide attempt (including an actual, interrupted\n             or aborted attempt), or has had suicidal ideation in the past 6 months as indicated\n             by a positive response (\"Yes\") to either Question 4 or Question 5 of the\n             Columbia-Suicide Severity Rating Scale (C-SSRS) at Visit 1\n\n          -  Subject whose seizures could not be reliably counted on a regular basis due to their\n             fast and repetitive occurrence (clusters or flurries)\n\n          -  Subject has history or presence of status epilepticus during the year preceding Visit\n             1 or during Baseline\n\n          -  Subject has history or presence of known psychogenic nonepileptic seizures\n\n          -  Subject has any clinical conditions (eg, bone marrow depression, chronic hepatic\n             disease, and/or severe renal impairment) which impair reliable participation in the\n             study or necessitate the use of medication not allowed by protocol\n\n          -  Subject is pregnant or lactating"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": {
            "#text": "29", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01653262", 
            "org_study_id": "N01395", 
            "secondary_id": "2011-005177-23"
        }, 
        "intervention": {
            "arm_group_label": "Brivaracetam", 
            "intervention_name": "Brivaracetam", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Etiracetam"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Brivaracetam", 
            "Levetiracetam", 
            "Epilepsy", 
            "Nonpsychotic behavior"
        ], 
        "lastchanged_date": "December 20, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Little Rock", 
                        "country": "United States", 
                        "state": "Arkansas"
                    }, 
                    "name": "103"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lexington", 
                        "country": "United States", 
                        "state": "Kentucky"
                    }, 
                    "name": "108"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "109"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Akron", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "106"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "110"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah"
                    }, 
                    "name": "102"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amiens", 
                        "country": "France"
                    }, 
                    "name": "203"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France"
                    }, 
                    "name": "201"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bernau", 
                        "country": "Germany"
                    }, 
                    "name": "303"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kehl-Kork", 
                        "country": "Germany"
                    }, 
                    "name": "300"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain"
                    }, 
                    "name": "502"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salford", 
                        "country": "United Kingdom"
                    }, 
                    "name": "603"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "France", 
                "Germany", 
                "Italy", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label, Multicenter, Single-arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects With Epilepsy Switching From Levetiracetam to Brivaracetam Due to Nonpsychotic Behavioral Side Effects Phase 3b", 
        "overall_official": {
            "affiliation": "+1 877 822 9493 (UCB)", 
            "last_name": "UCB Clinical Trial Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Italy: The Italian Medicines Agency", 
                "Spain: Spanish Agency of Medicines", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Percentage of subjects who achieved a clinically meaningful reduction of nonpsychotic behavioral side effects based on the Investigator's overall assessment from Study Entry to the end of the Treatment Period", 
            "safety_issue": "No", 
            "time_frame": "From Study Entry (Visit1, Week -1) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01653262"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Shift in the maximum intensity from Baseline to the end of the Treatment Period for side effects primarily associated with discontinuation of Levetiracetam (LEV) as determined by the Investigator", 
                "safety_issue": "No", 
                "time_frame": "From Baseline (maximum of 12 weeks prior to Study Entry at Week -1) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit"
            }, 
            {
                "description": "There are seven levels for the I-GEBSE:\nMarked improvement\nModerate improvement\nSlight improvement\nNo change\nSlight worsening\nModerate worsening\nMarked worsening", 
                "measure": "Change from Study Entry in nonpsychotic behavioral side effects to the end of the Treatment Period/Early Discontinuation Visit, measured by means of the Investigator Global Evaluation of nonpsychotic Behavioral Side Effects (I-GEBSE) scale", 
                "safety_issue": "No", 
                "time_frame": "From Study Entry (Visit1, Week -1) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit"
            }, 
            {
                "measure": "Number of subjects who have a complete abatement of nonpsychotic behavioral side effects for the last assessment during the Treatment Period, based on the Investigator's overall assessment", 
                "safety_issue": "No", 
                "time_frame": "From Baseline (maximum of 12 weeks prior to Study Entry at Week -1) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit"
            }, 
            {
                "measure": "Number of subjects who are free from nonpsychotic behavioral side effects over the entire Treatment Period", 
                "safety_issue": "No", 
                "time_frame": "From Visit 2 (Week 0) to Visit 6 (Week 12)"
            }, 
            {
                "measure": "Incidence of Treatment Emergent Adverse Events during the Study Period", 
                "safety_issue": "No", 
                "time_frame": "From Study Entry (Visit1, Week -1) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit"
            }, 
            {
                "measure": "Withdrawal due to an Adverse Event (AE) during the Study Period", 
                "safety_issue": "No", 
                "time_frame": "From Study Entry (Visit1, Week -1) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit"
            }, 
            {
                "measure": "Occurrence of Serious Adverse Events during the Study Period", 
                "safety_issue": "No", 
                "time_frame": "From Study Entry (Visit1, Week -1) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit"
            }, 
            {
                "description": "The POS frequency is standardized to a 28-day duration and changes in POS frequency are measured relative to the reported seizure counts for the 4 weeks prior to Visit 2 (Week 0).", 
                "measure": "Partial Onset Seizure (POS) frequency over the Treatment Period for subjects with focal Epilepsy", 
                "safety_issue": "No", 
                "time_frame": "From 4 weeks prior to Visit 2 (Week 0) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit"
            }, 
            {
                "description": "Generalized seizure days are standardized to a 28-day duration and changes in generalized seizure days are measured relative to the reported seizure counts for the 4 weeks prior to Visit 2 (Week 0).", 
                "measure": "Generalized seizure days over the Treatment Period for subjects with idiopathic generalized Epilepsy", 
                "safety_issue": "No", 
                "time_frame": "From 4 weeks prior to Visit 2 (Week 0) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit"
            }
        ], 
        "source": "UCB, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "UCB Pharma SA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}